Latest news
Stay in the know about our progress, and visit our Newsroom
Combining scientific excellence, financial capacity and dealmaking experience, we believe in the power of strong partnerships to pioneer for patients, together.
Lakefront’s longstanding relationship with Gilead Sciences and the successful acquisition of Ouro Medicines demonstrate our ability to structure innovative partnerships around high-quality assets and shared value creation.
Our collaboration terms with Gilead provide us with greater strategic flexibility to pursue new opportunities and transactions independently, expanding the universe of potential strategic targets.
We evaluate new opportunities against a high strategic, scientific, and value-creation bar, focusing on assets that complement our portfolio, and leverage and expand our development capabilities while addressing significant unmet patient needs.
If you believe your assets complement Lakefront’s strategy and portfolio, or would like to learn more about our in-licensing and partnering approach, please contact our Business Development team.
Please note that any business development proposals that are submitted via email or via our website will be considered non-confidential. No information exchange may be deemed confidential without a signed confidentiality or disclosure agreement from Lakefront Biotherapeutics.
Stay in the know about our progress, and visit our Newsroom
Looking for information about our company, our stock and our financials?